A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910